Search Results

Science 37, a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets.

Science 37 Holdings, Inc., announced its selection as winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program.

Science 37 Holdings, Inc. announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.

Science 37 Holdings, Inc., a leader in enhancing patient access to clinical trials, announced the final enrollment figures from its 20-month engagement with a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders.

The antipsychotic drugs market was valued at USD 18.04 billion in 2023 and is expected to reach around USD 37.40 billion by 2032, rising at a CAGR of 7.8% from 2024 to 2032.

Science 37 Holdings, Inc. today announced the launch of a stand-alone Patient Recruitment Solution to deliver patients to sites that are eligible, medically reviewed, and fully consented.

Oryzon Genomics, S.A. today announced that it will present final data from its Phase IIb PORTICO trial, which investigated the efficacy of vafidemstat in the treatment of Borderline Personality Disorder (BPD), as an oral presentation at the 37th European College of Neuropsychopharmacology (ECNP) annual conference, to be held on September 21-23, 2024 in Milan, Italy.

The global rapid microbiology testing market was valued at 5.2 billion in 2022 and is anticipated to reach around 12.37 billion by 2032, expanding at a CAGR of 9.1% from 2023 to 2032.

Science 37 Holdings, Inc. disclosed the latest enrollment figures resulting from its Metasite™ and Patient Recruitment partnership with a leading biotech company whose asthma drug is currently undergoing a Phase 3 clinical trial.

eMed, LLC (“eMed”) today announced that its wholly-owned subsidiary, Marlin Merger Sub Corporation, a Delaware corporation (“Purchaser”), has commenced a cash tender offer to purchase all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: SNCE) (“Science 37") for a price of $5.75 per share (the “Offer”).